{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:58:00Z","timestamp":1790517480894,"version":"4.1.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2018.00742","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T04:49:41Z","timestamp":1547786981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine"],"prefix":"10.3389","volume":"9","author":[{"given":"Florence","family":"Noble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee","year":"2009","journal-title":"Am J Public Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.clinthera.2013.10.001","article-title":"Pain as the fifth vital sign: exposing the vital need for pain education","volume":"35","author":"Morone","year":"2013","journal-title":"Clin Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1521-0391.2010.00086.x","article-title":"Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment","volume":"19","author":"Maremmani","year":"2010","journal-title":"Am J Addict."},{"key":"B4","first-page":"567","article-title":"International Union of Pharmacology. XII. Classification of opioid receptors","volume":"48","author":"Dhawan","year":"1996","journal-title":"Pharmacol Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0165-6147(98)01279-6","article-title":"Opioids: first lessons from knockout mice","volume":"20","author":"Kieffer","year":"1999","journal-title":"Trends Pharmacol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1600-0773.1973.tb01477.x","article-title":"Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex","volume":"32","author":"Terenius","year":"1973","journal-title":"Acta Pharmacol Toxicol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1073\/pnas.70.7.1947","article-title":"Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate","volume":"70","author":"Simon","year":"1973","journal-title":"Proc Natl Acad Sci USA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1126\/science.179.4077.1011","article-title":"Opiate receptor: demonstration in nervous tissue","volume":"179","author":"Pert","year":"1973","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/258577a0","article-title":"Identification of two related pentapeptides from the brain with potent opiate agonist activity","volume":"258","author":"Hughes","year":"1975","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-med-062613-093100","article-title":"Opioid receptors","volume":"67","author":"Stein","year":"2016","journal-title":"Annu Rev Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1073\/pnas.90.14.6736","article-title":"Cloning and functional comparison of kappa and delta opioid receptors from mouse brain","volume":"90","author":"Yasuda","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B12","first-page":"8","article-title":"Molecular cloning and functional expression of a mu-opioid receptor from rat brain","volume":"44","author":"Chen","year":"1993","journal-title":"Mol Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12048","DOI":"10.1073\/pnas.89.24.12048","article-title":"The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization","volume":"89","author":"Kieffer","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1126\/science.1335167","article-title":"Cloning of a delta opioid receptor by functional expression","volume":"258","author":"Evans","year":"1992","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neuropharm.2013.08.028","article-title":"15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse","volume":"76","author":"Charbogne","year":"2014","journal-title":"Neuropharmacology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/BF00432213","article-title":"Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning","volume":"86","author":"Mucha","year":"1985","journal-title":"Psychopharmacology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/npp.2008.128","article-title":"Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice","volume":"34","author":"Chefer","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.biopsych.2010.10.021","article-title":"Deletion of the delta opioid receptor gene impairs place conditioning but preserves morphine reinforcement","volume":"69","author":"Le Merrer","year":"2011","journal-title":"Biol Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","article-title":"Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010","volume":"132","author":"Jones","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"B22","article-title":"Opioid, overdose","volume-title":"StatPearls","author":"Schiller","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40122-018-0096-7","article-title":"A review of the opioid epidemic: what do we do about it?","volume":"7","author":"Shipton","year":"2018","journal-title":"Pain Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1097\/PR9.0000000000000599","article-title":"The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents","volume":"2","author":"Hauser","year":"2017","journal-title":"Pain Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/187447370801150611184218","article-title":"The misuse of prescription opioids: a threat for Europe?","volume":"8","author":"van Amsterdam","year":"2015","journal-title":"Curr Drug Abuse Rev."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.06.006.","article-title":"Role of pharmacokinetic and pharmacodynamic parameters in neuroadaptations induced by drugs of abuse, with a focus on opioids and psychostimulants","author":"Marie","year":"2018","journal-title":"Neurosci Biobehav Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0024-3205(83)90616-1","article-title":"Evidence from opiate binding studies that heroin acts through its metabolites","volume":"33","author":"Inturrisi","year":"1983","journal-title":"Life Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/157488406775268219","article-title":"Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature","volume":"1","author":"Rook","year":"2006","journal-title":"Curr Clin Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1126\/science.178.4064.984","article-title":"Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection","volume":"178","author":"Oldendorf","year":"1972","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s002130050956","article-title":"Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans","volume":"143","author":"Comer","year":"1999","journal-title":"Psychopharmacology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cpt1972135part1633","article-title":"The levels of methadone in the plasma in methadone maintenance","volume":"13","author":"Inturrisi","year":"1972","journal-title":"Clin Pharmacol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.008","article-title":"Relative bioavailability of different buprenorphine formulations under chronic dosing conditions","volume":"74","author":"Strain","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"B35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00213-003-1718-1","article-title":"Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice","volume":"173","author":"Wang","year":"2004","journal-title":"Psychopharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"J Clin Invest."},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40291-017-0311-y","article-title":"Pharmacogenetics of methadone response","volume":"22","author":"Fonseca","year":"2018","journal-title":"Mol Diagn Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/10550490500419029","article-title":"Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine","volume":"15","author":"McCance-Katz","year":"2006","journal-title":"Am J Addict."},{"key":"B39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.taap.2005.08.002","article-title":"Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation","volume":"212","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol Appl Pharmacol."},{"key":"B40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0028-3908(84)90201-6","article-title":"Binding of buprenorphine to opiate receptors. Regulation by guanyl nucleotides and metal ions","volume":"23","author":"Villiger","year":"1984","journal-title":"Neuropharmacology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/sj.clpt.6100025","article-title":"Mechanism-based PK\/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers","volume":"81","author":"Yassen","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.toxlet.2012.12.021","article-title":"Comparison of tolerance to morphine-induced respiratory and analgesic effects in mice","volume":"217","author":"Mohammed","year":"2013","journal-title":"Toxicol Lett."},{"key":"B43","first-page":"496","article-title":"Signal transduction correlates of Mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP\u03b3S binding in mMOR-CHO cells and rat thalamus","volume":"285","author":"Selley","year":"1998","journal-title":"J Pharmacol Exp Ther."},{"key":"B44","first-page":"688","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/ADM.0b013e31806c9202","article-title":"Buprenorphine: the basic pharmacology revisited","volume":"1","author":"Cowan","year":"2007","journal-title":"J Addict Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/bph.12222","article-title":"Efficacy and ligand bias at the \u03bc-opioid receptor","volume":"169","author":"Kelly","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jcpt.12196","article-title":"The clinical analgesic efficacy of buprenorphine","volume":"39","author":"Raffa","year":"2014","journal-title":"J Clin Pharm Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bbi.2007.12.013","article-title":"Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function","volume":"22","author":"Sacerdote","year":"2008","journal-title":"Brain Behav Immun."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2017.1342047","article-title":"Cognitive function is largely intact in methadone maintenance treatment patients","author":"Elkana","year":"2017","journal-title":"World J Biol Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1744-859X-10-17","article-title":"Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?","volume":"10","author":"Maremmani","year":"2011","journal-title":"Ann Gen Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000321465","article-title":"Effect of psychiatric severity on the outcome of methadone maintenance treatment","volume":"17","author":"Pani","year":"2011","journal-title":"Eur Addict Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12991-016-0109-z","article-title":"The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment","volume":"15","author":"Bizzarri","year":"2016","journal-title":"Ann Gen Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jama.283.10.1303","article-title":"Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial","volume":"283","author":"Sees","year":"2000","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1093\/pubmed\/fdv150","article-title":"Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience","volume":"38","author":"Wright","year":"2016","journal-title":"J Public Health"},{"key":"B58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00139709-200625020-00002","article-title":"Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences","volume":"25","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1002396","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case\u2013control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"key":"B61","doi-asserted-by":"publisher","first-page":"577","DOI":"10.17179\/excli2015-553","article-title":"A systematic review of the cardiotoxicity of methadone","volume":"14","author":"Alinejad","year":"2015","journal-title":"EXCLI J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ADM.0000000000000353","article-title":"Methadone and the QTc interval: paucity of clinically significant factors in a retrospective cohort","volume":"11","author":"Bart","year":"2017","journal-title":"J Addict Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pnpbp.2017.09.008","article-title":"Cognitive effects of labeled addictolytic medications","volume":"81","author":"Pujol","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000441470","article-title":"Sexual dysfunction in men receiving methadone maintenance treatment: clinical history and psychobiological correlates","volume":"22","author":"Gerra","year":"2016","journal-title":"Eur Addict Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ijir.2014.18","article-title":"Clinical factors associated with sexual dysfunction among men in methadone maintenance treatment and buprenorphine maintenance treatment: a meta-analysis study","volume":"26","author":"Yee","year":"2014","journal-title":"Int J Impot Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00213-014-3785-x","article-title":"Striatal dopamine D1 and D2 receptors are differentially regulated following buprenorphine or methadone treatment","volume":"232","author":"Allouche","year":"2015","journal-title":"Psychopharmacology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pnpbp.2012.10.013","article-title":"Different patterns of administration modulate propensity of methadone and buprenorphine to promote locomotor sensitization in mice","volume":"40","author":"Allouche","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.2147\/DDDT.S72543","article-title":"Advances in the delivery of buprenorphine for opioid dependence","volume":"11","author":"Rosenthal","year":"2017","journal-title":"Drug Des Dev Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S0376-8716(03)00057-7","article-title":"Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?","volume":"70","author":"Mendelson","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1017\/S146114571400025X","article-title":"Rewarding or aversive effects of buprenorphine\/naloxone combination (Suboxone) depend on conditioning trial duration","volume":"17","author":"Canestrelli","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"B72","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/10550880903014767","article-title":"Diversion of buprenorphine\/naloxone coformulated tablets in a region with high prescribing prevalence","volume":"28","author":"Monte","year":"2009","journal-title":"J Addict Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.drudis.2017.07.002","article-title":"Mu-Opioid receptor biased ligands: a safer and painless discovery of analgesics?","volume":"22","author":"Madariaga-Maz\u00f3n","year":"2017","journal-title":"Drug Discov Today"},{"key":"B74","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fphar.2014.00280","article-title":"Opioid receptor desensitization: mechanisms and its link to tolerance","volume":"5","author":"Allouche","year":"2014","journal-title":"Front Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/35047086","article-title":"Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","article-title":"A randomized, phase 2 study investigating TRV130, a biased ligand of the \u03bc-opioid receptor, for the intravenous treatment of acute pain","volume":"157","author":"Viscusi","year":"2016","journal-title":"Pain"},{"key":"B79","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the \u03bc-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J Psychopharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors - improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2018","journal-title":"Br J Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J Pharmacol Exp Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"eaar3483","DOI":"10.1126\/scitranslmed.aar3483","article-title":"A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates","volume":"10","author":"Ding","year":"2018","journal-title":"Sci Transl Med."},{"key":"B86","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/288286a0","article-title":"The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice","volume":"288","author":"Roques","year":"1980","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrd3673","article-title":"Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain","volume":"11","author":"Roques","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"B88","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/0306-4522(85)90147-2","article-title":"Comparison of substance P and enkephalin distribution in rat brain: an overview using radioimmunocytochemistry","volume":"14","author":"McLean","year":"1985","journal-title":"Neuroscience"},{"key":"B89","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0304-3959(00)00382-1","article-title":"Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration","volume":"90","author":"Boudinot","year":"2001","journal-title":"Pain"},{"key":"B90","first-page":"397","article-title":"Potentiation of enkephalin action by peptidase inhibitors in rat locus ceruleus in vitro","volume":"243","author":"Williams","year":"1987","journal-title":"J Pharmacol Exp Ther."},{"key":"B91","first-page":"669","article-title":"Role of different brain structures in the expression of the physical morphine withdrawal syndrome","volume":"261","author":"Maldonado","year":"1992","journal-title":"J Pharmacol Exp Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jsat.2014.05.012","article-title":"Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence","volume":"47","author":"H\u00e4mmig","year":"2014","journal-title":"J Subst Abuse Treat."},{"key":"B93","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.psc.2012.03.002","article-title":"Advances in opioid antagonist treatment for opioid addiction","volume":"35","author":"Ling","year":"2012","journal-title":"Psychiatr Clin North Am."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13722-016-0068-3","article-title":"Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know","volume":"12","author":"Kerensky","year":"2017","journal-title":"Addict Sci Clin Pract."},{"key":"B96","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/00000542-197410000-00010","article-title":"Reversal of Morphine Anesthesia with Naloxone","volume":"41","author":"Johnstone","year":"1974","journal-title":"Anesthesiology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000542-200607000-00012","article-title":"Naloxone reversal of buprenorphine-induced respiratory depression","volume":"105","author":"van Dorp","year":"2006","journal-title":"Anesthesiology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1517\/14740338.2015.1037274","article-title":"Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review","volume":"14","author":"Kim","year":"2015","journal-title":"Expert Opin Drug Saf."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2018.00742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T04:49:45Z","timestamp":1547786985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2018.00742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":98,"alternative-id":["10.3389\/fpsyt.2018.00742"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2018.00742","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"article-number":"742"}}